Nivolumab Injection Dealers

Opdyta 40mg Injection is used in the treatment of non-small cell lung cancer, kidney cancer, head and neck cancer, melanoma, Hodgkin's disease, and liver cancer.Opdyta 40mg Injection is given as an infusion into vein by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.Some common side effects of this medicine include rash, weakness, headache, and fever. Some serious side effects which may occur during infusion include chills or shaking, itching, rash, flushing, difficulty breathing and dizziness. Hence, your doctor will check you timely after infusion for allergic reaction.Before taking it, tell your doctor if have lung disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. Use of effective contraception by both males and females during treatment is important to avoid pregnancy. 

• Type: INJECTION
• Brand Name: OPDIVO
• Manufacturer: BRISTOL

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat kidney cancer (renal cell carcinoma) in certain people when their cancer has spread.

• Brand Name: Opdivo Nivolumab Injection

Product Description   We are engaged as the foremost Manufacturer and Wholesaler of Pharmaceutical Injections, Pharma Injections, Pharmaceutical Tablets, IV Infusions, Pharmaceutical Capsules and many more. Our products are high in demand due to their premium quality and affordable prices. Furthermore, we ensure to timely deliver these products to our clients, through this we have gained a huge clients base in the market. Under the leadership of our mentor, "Mr. Abdul Moheen", we have been able to attain a commendable position in this domain. His excellent management skills, profound experience, and innovative business ideas has helped us in catering to the huge clientele across the nation.

• Dosage Form: Injection
• Strength: 40mg & 100mg
• Treatment: Lung Cancer
• Storage: 2 Degree C to 8 Degree C (36 Degree F to 46 Degree F)
• Dosage: Take Opdivo Vial Only as per the Dose and Duration Suggested By Your Doctor
• Pack Size: 1 Vial

• Application: Hospital/Clinic
• Brand Name: OPDYTA
• Side Effects: black, tarry stools,blood in the urine,chest pain
• Packing Size: 100mg
• Uses: Intravenous

• Usage/Application: Clinic , Hospital
• Brand Name: Opdyta
• Composition: Nivolumab
• Manufacturer: Bristol Myers Squibb
• Packaging Size: vial
• Dose Strength: 40/100 mg

• Form: Liquid
• Strength: 100mg
• Manufacturer: BMS India Pvt Ltd
• MRP: 9500 / Box
• Use: Treat Cancer
• Life: 1 year 11 month from the date of Manufacturing

• API Form: Liquid
• Treatment: Used to Treat Esophageal or Gastroesophageal Junction Cancer
• Dosage: As per Doctor's Prescription
• Storage: Cool and Dry Place
• Best Before: 36 Months from Manufacturing

A drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that express the protein PD-L1 or that have certain mutations (changes) in genes involved in DNA repair. Nivolumab is used alone or with other drugs to treat certain types of esophageal cancer, gastroesophageal junction cancer, stomach cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), melanoma, hepatocellular carcinoma (a type of liver cancer), squamous cell carcinoma of the head and neck, classic Hodgkin lymphoma, urothelial carcinoma (a type of bladder or urinary tract cancer), and malignant pleural mesothelioma. It is also being studied in the treatment of other types of cancer. Nivolumab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Opdivo.   Nivolumab is approved to be used alone or with other drugs to treat: Classic Hodgkin lymphoma Colorectal cancer Esophageal cancer or gastroesophageal junction adenocarcinoma. Gastric (stomach) cancer, gastroesophageal junction adenocarcinoma, or esophageal cancer Malignant pleural mesothelioma. Melanoma Non-small cell lung cancer. Renal cell carcinoma Squamous cell carcinoma of the head and neck Urothelial carcinoma   Nivolumab was approved for medical use in the United States in 2014. It is on the World Health Organization’s List of Essential Medicines. It is made using Chinese hamster ovary cells.   Nivolumab is the second FDA-approved systemic therapy for mesothelioma and is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.   The combination of nivolumab with ipilimumab is used for the first-line treatment of adults with malignant pleural mesothelioma (MPM) that cannot be removed by surgery.   In April 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab, in combination with certain types of chemotherapy, for the initial treatment of people with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.   In May 2021, the U.S. FDA approved nivolumab for people with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.[8]   In August 2021, the U.S. FDA approved nivolumab for the adjuvant treatment of people with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.[16]   In May 2022, the U.S. FDA expanded the indication to include the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).